Ethiopia will receive 13 million praziquantel tablets in 2015
12 December 2014 | By Merck KGaA
Merck supports the World Health Organization (WHO) to fight the parasitic worm disease schistosomiasis in Africa...
List view / Grid view
News
Changes in Roche Board of Directors and enlarged Corporate Executive Committee
12 December 2014 | By Roche
At its December meeting, the Board of Directors (BoD) of Roche Holding recommended first proposals for approval by the AGM, scheduled for 3 March 2015...
Janssen and USAID collaborate to expand access to anti-multidrug-resistant tuberculosis (MDR-TB) compound
12 December 2014 | By Johnson & Johnson
Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria...
Patent cliff means pharmaceutical companies will lose $65 billion by 2019, says GlobalData
11 December 2014 | By GlobalData
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData...
Otsuka and Lundbeck´s brexpiprazole demonstrates statistically significant effects in New Phase III Studies in adult patients with schizophrenia
11 December 2014 | By H. Lundbeck A/S
... presented at the American College of Neuropsychopharmacology annual meeting.
Abbott’s pioneering, infectious disease testing platform, IRIDICA, now available in Europe
11 December 2014 | By Abbott
Abbott announced its innovative diagnostic platform, known as IRIDICA, is now available in Europe and other CE-Mark recognized countries...
Gielad presents follow-up data from idelalisib (zydelig®) registrational studies in patients with chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma
11 December 2014 | By Gilead Sciences
Results describing long-term safety and disease control presented at the 56th American Society of Hematology Annual Meeting...
Bristol-Myers Squibb announces dividend
10 December 2014 | By Bristol-Myers Squibb Company
The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock of the corporation...
New follow-up data for IMBRUVICA® (ibrutinib) presented at ASH show longer term efficacy in patients with chronic lymphocytic Leukaemia and mantle cell lymphoma
10 December 2014 | By Janssen
Janssen-Cilag International NV (Janssen) is pleased to announce the presentation of new longer term follow-up data from two IMBRUVICA® (ibrutinib) studies at the American Society of Hematology (ASH) meeting in San Francisco, CA. IMBRUVICA is a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.
Roche’s preeclampsia test helps to predict this life-threatening condition in pregnant women at risk
10 December 2014 | By Roche
New data demonstrate high prognostic value of Elecsys blood test...
Pricing for new drugs lacks transparency
10 December 2014 | By The Royal Society of Medicine
The system that allows patients rapid access to expensive new treatments lacks transparency and penalises small and low-income countries unable to negotiate lower prices with pharmaceutical manufacturers...
The Prince of Wales marks the 10th anniversary of International Health Partners as they launch EURMED
9 December 2014 | By Janssen
International Health Partners (IHP) in partnership with Banco Farmaceutico and Action Medeor has launched EURMED; a unique industry collaboration that enables the donation of medicines for disaster relief and humanitarian aid.
Roche presents data for hemophilia A therapy ACE910
9 December 2014 | By Roche
Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting...
Scottish Medicines Consortium accepts use of Alimta (pemetrexed) for treatment of non-small cell lung cancer
9 December 2014 | By Eli Lilly and Company
On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta (pemetrexed) monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (other than predominantly squamous cell histology) in patients whose disease has not progressed immediately following platinum-based chemotherapy...
Lilly and Incyte announce positive top-line results from Phase 3 trial of baricitinib in moderate to severe rheumatoid arthritis
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.
